These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38814433)

  • 21. Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial.
    Reich K; Kristensen LE; Smith SD; Rich P; Sapin C; Leage SL; McKenzie R; Schuster C; Riedl E; Gooderham M
    Dermatol Pract Concept; 2022 May; 12(2):e2022104. PubMed ID: 35646453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials.
    Eder L; Tony HP; Odhav S; Agirregoikoa EG; Korkosz M; Schwartzman S; Sprabery AT; Gellett AM; Park SY; Bertram CC; Ogdie A
    Rheumatol Ther; 2022 Jun; 9(3):919-933. PubMed ID: 35397092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52.
    Behrens F; Leage SL; Sapin C; Baou CE; De La Torre I; Meszaros G; Schett G; Combe B; van den Bosch F; Gossec L
    Clin Rheumatol; 2021 Dec; 40(12):4943-4954. PubMed ID: 34515902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
    Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
    Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
    Coates LC; Mease P; Kronbergs A; Helt C; Sandoval D; Park SY; Combe B; Nash P; Deodhar A
    Clin Rheumatol; 2022 Oct; 41(10):3035-3047. PubMed ID: 35674861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
    Blauvelt A; Papp KA; Sofen H; Augustin M; Yosipovitch G; Katoh N; Mrowietz U; Ohtsuki M; Poulin Y; Shrom D; Burge R; See K; Mallbris L; Gordon KB
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1004-1013. PubMed ID: 28190255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
    Wasel N; Thaçi D; French LE; Conrad C; Dutronc Y; Gallo G; Berggren L; Lacour JP
    Dermatol Ther (Heidelb); 2020 Aug; 10(4):663-670. PubMed ID: 32415575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Elewski BE; Blauvelt A; Gallo G; Wolf E; McKean-Matthews M; Burge R; Merola JF; Gottlieb AB; Guenther LC
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):911-920. PubMed ID: 35279805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
    Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
    J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
    Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
    Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Papp KA; Leonardi CL; Blauvelt A; Reich K; Korman NJ; Ohtsuki M; Paul C; Ball S; Cameron GS; Erickson J; Zhang L; Mallbris L; Griffiths CEM
    Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials.
    Tillett W; Lin CY; Trevelin Sprabery A; Birt JA; Kavanaugh A
    Clin Exp Rheumatol; 2020; 38(6):1227-1230. PubMed ID: 32452352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
    Yosipovitch G; Reich A; Steinhoff M; Beselin A; Kent T; Dossenbach M; Berggren L; Henneges C; Luger T
    Dermatol Ther (Heidelb); 2018 Dec; 8(4):621-637. PubMed ID: 30465321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
    Genovese MC; Combe B; Kremer JM; Tsai TF; Behrens F; Adams DH; Lee C; Kerr L; Nash P
    Rheumatology (Oxford); 2018 Nov; 57(11):2001-2011. PubMed ID: 30053162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
    Gottlieb AB; Strand V; Kishimoto M; Mease P; Thaçi D; Birt J; Lee CH; Shuler CL; Lin CY; Gladman DD
    Rheumatology (Oxford); 2018 Oct; 57(10):1777-1788. PubMed ID: 29945203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
    Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
    Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.
    Guenther L; Warren RB; Cather JC; Sofen H; Poulin Y; Lebwohl M; Terui T; Potts Bleakman A; Zhu B; Burge R; Reich K; van de Kerkhof P
    J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1867-1875. PubMed ID: 28573743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.
    Paul C; Guenther L; Torii H; Sofen H; Burge R; Lin CY; Potts Bleakman A; Mallbris L; Poulin Y
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):68-72. PubMed ID: 28881462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
    Armstrong A; González-Cantero A; Khattri S; Muzy G; Malatestinic WN; Lampropoulou A; Feely M; See SK; Mert C; Blauvelt A
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.